Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  TESARO Inc    TSRO

TESARO INC (TSRO)
Mes dernières consult.
Most popular
Report
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/12/2018 01/16/2018 01/17/2018 01/18/2018 01/19/2018 Date
69.59(c) 65.52(c) 61.86(c) 63.5(c) 63.91(c) Last
1 749 596 3 274 256 2 198 371 3 025 154 1 292 650 Volume
-2.89% -5.85% -5.59% +2.65% +0.65% Change
More quotes
Financials ($)
Sales 2017 229 M
EBIT 2017 -425 M
Net income 2017 -445 M
Finance 2017 363 M
Yield 2017 -
Sales 2018 396 M
EBIT 2018 -371 M
Net income 2018 -383 M
Finance 2018 224 M
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales2017 13,6x
EV / Sales2018 8,21x
Capitalization 3 476 M
More Financials
Company
TESARO, Inc. is an oncology-focused biopharmaceutical company, which engages in the research and development of biopharmaceutical products.It focuses on oncology-based therapeutics and its products include: Rolapitant and Niraparib.The company was founded by Leon Moulder, Jr., Mary Lynne Hedley,... 
More about the company
Surperformance© ratings of TESARO Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on TESARO INC
01/19 ROBBINS ARROYO LLP : Tesaro, Inc. (TSRO) Misled Shareholders According to a Rece..
01/19 SHAREHOLDER ALERT - BRONSTEIN, GEWIR : March 19, 2018
01/19 TSRO The Law Offices of Vincent Wong Notifies Investors of an Investigation I..
01/18 Law Offices of Howard G. Smith Commences Investigation on Behalf of Tesaro, I..
01/18 Levi & Korsinsky, LLP Reminds Investors of an Investigation Involving Possibl..
01/18 Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against TE..
01/18 TESARO : MetroWest Business Digest for Jan. 18, 2018
01/17 GLANCY PRONGAY & MURRAY LLP : Commences Investigation on Behalf of Tesaro, Inc. ..
01/17 TESARO Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceedin..
01/16 Rosen Law Firm Announces Investigation of Securities Claims Against TESARO, I..
More news
Sector news : Bio Therapeutic Drugs
01/17 CELGENE : Conducts Deal Talks With Juno -- WSJ
01/16 CELGENE : in Talks to Buy Juno Therapeutics -- Update
01/16 CELGENE : in Talks to Buy Juno Therapeutics
01/12 Drugmakers see a pricing blueprint in an $850,000 gene therapy
01/12 SPARK'S PRICE FOR LUXTURNA BLINDNESS : Icer
More sector news : Bio Therapeutic Drugs
Latest Tweets
06:51aSCANA : Lifshitz & Miller LLP Announces Investigation of AMC Entertainmen.. 
01/20TESARO $TSRO Stock Price Down 5.6%  
01/20SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors.. 
01/20TESARO $TSRO Price Target Cut to $156.00  
01/19$IBB $XBI $BGNE $EDGE $SNDX $OFIX $TTOO $AFAM $RDY $DRNA $ONCS $JUNO $EDIT $T.. 
More tweets
Qtime:83
News from SeekingAlpha
01/19 U.S. BIOTECH/PHARMA SECTOR DAILY OBS : Jan. 18, 2018
01/18 3 THINGS IN BIOTECH YOU SHOULD LEARN : January 17, 2018
01/17 YOUR DAILY PHARMA SCOOP : Eiger Selloff, Novartis' Cosentyx, RXi Outlines Busine..
01/16 TESARO updates U.S. Varubi label after reports of serious hypersensitivity re..
01/16 Biotech Daily Digest For January 16th
Chart TESARO INC
Duration : Period :
TESARO Inc Technical Analysis Chart | TSRO | US8815691071 | 4-Traders
Technical analysis trends TESARO INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 134 $
Spread / Average Target 109%
EPS Revisions
Managers
NameTitle
Leon O. Moulder Chief Executive Officer & Director
Mary Lynne Hedley President, Chief Operating Officer & Director
David M. Mott Chairman
Timothy R. Pearson EVP, Chief Financial & Accounting Officer
Martin H. Huber Chief Medical Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
TESARO INC-23.37%3 476
GILEAD SCIENCES14.10%105 754
VERTEX PHARMACEUTICALS4.76%39 951
REGENERON PHARMACEUTICALS-0.50%39 917
GENMAB10.50%11 762
EXELIXIS, INC.-9.57%8 284